INTELLIA THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
INTELLIA THERAPEUTICS INC. - More news...
INTELLIA THERAPEUTICS INC. - More news...
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intellia Therapeutics, Inc - NTLA
- Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
- Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
- Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
- Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
- Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
- Intellia Therapeutics Announces New Date for Upcoming Investor Webcast
- Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
- Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
- Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm
- Intellia Therapeutics Announces CFO Transition
- Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
- Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
- Intellia Therapeutics Names Brian Goff to its Board of Directors
- Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
- Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
- Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
